Wednesday , January 17 2018
Home / KEEP BUT DO NOT DISPLAY / Alerts (page 3)

Alerts

Ordered by most recent

FDA Finalizes Menu, Vending Machine Calorie Labeling Rules

FDA Finalizes Menu, Vending Machine Calorie Labeling Rules  The FDA has finalized two rules that require chain restaurants, retail food establishments and vending machines with 20 or more locations to list calorie information on a menu or menu board. Gabapentin Capsules USP 300 mg Recall  Aurobindo Pharma USA is voluntarily …

Read More »

French Company Granted Rights to Implantable Pump

French Company Granted Rights to Implantable Pump Sevier, a pharmaceutical company based in France, agreed to make payments totaling over $1B to privately held Intarcia Therapeutics, Inc. for the rights to co-develop the company’s implantable pump, designed to deliver one year’s worth of the GLP-1 exenatide.

Read More »

Novo Launches NovoRapid PumpCart in Europe

  Novo Nordisk has launched the NovoRapid PumpCart, the first prefilled pump cartridge with an insulin analog that has been specifically designed for insulin pumps. The new treatment solution contains NovoRapid (insulin aspart) — a rapid-acting insulin. The 1.6 ml cartridge was developed in a non-exclusive partnership between Roche Diabetes Care …

Read More »

Trulicity Once-Weekly GLP-1 Shipping Now

Trulicity Once-Weekly GLP-1 Shipping Now  Eli Lilly and Company announced that Trulicity, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with once-weekly dosing in the Trulicity pen, was approved by the FDA on September 18, 2014, and is shipping to distributors now.

Read More »

ACO Update

After two years, only 19 of original 32 CMS Pioneer ACO’s still participating. See this week’s Tool for Your Practice and Letter from the Editor.

Read More »

FDA Approves Once-Weekly Dulaglutide for Type 2 Diabetes

FDA Approves Once-Weekly Dulaglutide for Type 2 Diabetes Once-weekly dulaglutide was approved based on six clinical trials involving a total of 3,342 patients who received the drug. It was studied as a stand-alone therapy and in combination with metformin, sulfonylurea, thiazolidinedione, and prandial insulin. 

Read More »

FDA Approves Weight Loss Drug Contrave

FDA Approves Weight Loss Drug Contrave. See this week’s Item #4. FDA Advisory Panel Recommends Approval of Novo Nordisk’s liraglutide (used now as Victoza to treat type 2 diabetes ) for use in chronically obese patients with at least one weight-related health issue. More news to come. The new drug would be …

Read More »